Amicus Therapeutics, Inc.
FOLD
$14.38
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.55% | 9.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.55% | 9.29% | |||
| Cost of Revenue | 36.37% | 27.93% | |||
| Gross Profit | 6.06% | 7.26% | |||
| SG&A Expenses | 30.04% | 6.50% | |||
| Depreciation & Amortization | 1.23% | 1.19% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.58% | -17.03% | |||
| Operating Income | -53.47% | 540.93% | |||
| Income Before Tax | -90.83% | 278.69% | |||
| Income Tax Expenses | -91.44% | 223.88% | |||
| Earnings from Continuing Operations | -90.23% | 170.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -90.23% | 170.87% | |||
| EBIT | -53.47% | 540.93% | |||
| EBITDA | -50.63% | 710.52% | |||
| EPS Basic | -90.20% | 170.83% | |||
| Normalized Basic EPS | -90.78% | 296.05% | |||
| EPS Diluted | -96.43% | 170.83% | |||
| Normalized Diluted EPS | -90.72% | 294.92% | |||
| Average Basic Shares Outstanding | 0.18% | 0.07% | |||
| Average Diluted Shares Outstanding | -0.45% | 0.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||